Review of regulatory recommendations for orphan drug submissions in the Netherlands and Scotland: focus on the underlying pharmacoeconomic evaluations.

[1]  王林,et al.  Orphanet , 2011 .

[2]  H. Büller,et al.  Orphan drug development across Europe: bottlenecks and opportunities. , 2008, Drug discovery today.

[3]  J. Torrent-Farnell,et al.  Does orphan drug legislation really answer the needs of patients? , 2008, The Lancet.

[4]  M. Sheehan.  Orphan drugs and the NHS , 2005, BMJ : British Medical Journal.

[5]  D. Hughes,et al.  Drugs for exceptionally rare diseases: do they deserve special status for funding? , 2005, QJM : monthly journal of the Association of Physicians.

[6]  C. McCabe,et al.  Orphan drugs and the NHS: should we value rarity? , 2005, BMJ : British Medical Journal.

[7]  A. Burls,et al.  Commissioning for rare diseases: view from the frontline , 2005, BMJ : British Medical Journal.

[8]  H. Kohli.  Scottish Medicines Consortium. , 2005, The National medical journal of India.

[9]  R. Busse,et al.  Ethical issues in funding orphan drug research and development , 2005, Journal of Medical Ethics.

[10]  M. Sculpher,et al.  Decision-making by healthcare payers. , 2002, Respiratory medicine.